title: Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung.
abstract: Our aim was to determine whether or not non-small-cell lung cancer is squamous cell carcinoma (SQCC); even in small samples, it is essential in view of the side effects attendant on new therapeutics. Lung adenocarcinoma (ADC) with the EML4-ALK fusion gene has been described as demonstrating mucinous cribriform/acinar growth and signet-ring cells, sometimes partially simulating SQCC. We investigated the relation among morphology, anaplastic lymphoma kinase (ALK) rearrangement, and immunophenotype in 321 ADCs by tissue microarray using SQCC markers cytokeratin (CK)5/6, CK14, desmocollin-3, desmoglein-3, p40, p63 versus ADC markers thyroid transcription factor (TTF)-1 and napsin A. Unlike 312 ALK-negative ADCs, 9 ALK-positive cases were negative for 4 SQCC markers. Only 1 ALK-positive ADC showing assertive morphology was positive for CK5/6 and p63 as well as for TTF-1 and napsin A. Coexpression of TTF-1/p40 was not observed, unlike that of TTF-1/p63 reported previously. There was no statistically significant difference between ALK-negative and ALK-positive ADC by immunohistochemical profiling.
authors.affiliation: 1Kobe University Hospital, Kobe, Hyogo, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Sakai
authors.forename: Tokiko
authors.initials: T
authors.lastname: Nakai
authors.forename: Chiho
authors.initials: C
authors.lastname: Ohbayashi
authors.forename: Naoko
authors.initials: N
authors.lastname: Imagawa
authors.forename: Emmy
authors.initials: E
authors.lastname: Yanagita
authors.forename: Rumiko
authors.initials: R
authors.lastname: Satake
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nitta
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Kajimoto
authors.forename: Toshiko
authors.initials: T
authors.lastname: Sakuma
authors.forename: Tomoo
authors.initials: T
authors.lastname: Itoh
mesh_terms: D000230:Adenocarcinoma / Q000145:classification* / Q000235:genetics / Q000378:metabolism; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000145:classification* / Q000235:genetics / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000145:classification* / Q000235:genetics / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000145:classification* / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D046888:Tissue Array Analysis
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK rearrangement; adenocarcinoma; immunohistochemical profiling; non-small-cell lung cancer; squamous cell carcinoma; tissue microarray